Assessment of variants associated with resistance in NS3, NS5A and NS5B region in genotype 1b HCV infected patients

Assessment of variants associated with resistance in NS3, NS5A and NS5B region in genotype 1b HCV infected patients - Assessment of RAVs

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000018857

Enrollment

300

Registered

2015-10-01

Start date

2015-09-14

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

patients infected with genotype 1 HCV

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: HCV genotype 1 infected patients who recieve anti-viral therapy such as combination therapy with daclatasvis/asunaprevir, sofosbuvir/ledipasvir and ombitasvir/paritaprevir/ritonavir

Exclusion criteria

Exclusion criteria: patients infected with HCV other than genotype 1

Design outcomes

Primary

Measure	Time frame
the efficacy of antiviral therapy at post-treatment 12 and 24 weeks	—

Countries

Japan

Contacts

Public ContactYoshihito Uchida

Saitama Medical University Department of Gastroenterology & Hepatology

y_uchida@saitama-med.ac.jp049-276-1198

Outcome results